Wall Street Zen Downgrades CONMED to 'Buy' Rating

Analysts cite concerns over the company's recent performance and outlook.

Mar. 21, 2026 at 5:51am

Got story updates? Submit your updates here. ›

CONMED (NYSE:CNMD), a global medical technology company headquartered in Utica, New York, was downgraded from a "strong-buy" rating to a "buy" rating by equity research firm Wall Street Zen. The downgrade comes as CONMED has faced a number of challenges, including a drop in its stock price and mixed financial results.

Why it matters

CONMED is a major player in the medical device industry, particularly in the areas of orthopedics, general surgery, gastroenterology, and gynecology. The company's performance and outlook can have significant implications for its shareholders as well as the broader medical technology sector.

The details

In its research report, Wall Street Zen cited concerns over CONMED's recent financial performance and the company's future prospects. The analysts noted that CONMED's stock price has declined significantly in recent months, dropping from a 52-week high of $61.25 to a current level of around $36. The report also pointed to mixed financial results, with the company reporting better-than-expected earnings in its most recent quarter but also facing headwinds such as increased competition and pricing pressure.

  • CONMED's stock price has declined from a 52-week high of $61.25 to around $36 as of the most recent trading session.
  • The company reported its latest financial results on January 28, 2026.

The players

Wall Street Zen

An equity research firm that provides analysis and ratings on publicly traded companies.

CONMED Corporation

A global medical technology company headquartered in Utica, New York, that develops, manufactures, and markets a broad portfolio of surgical devices and accessories for minimally invasive procedures.

Got photos? Submit your photos here. ›

What they’re saying

“We must downgrade CONMED from a 'strong-buy' to a 'buy' rating due to the company's recent performance and the challenges it faces going forward.”

— Wall Street Zen Analyst

What’s next

Investors will be closely watching CONMED's upcoming earnings reports and any further updates from the company on its strategy and outlook.

The takeaway

The downgrade of CONMED by Wall Street Zen highlights the ongoing challenges facing the medical device industry, including increased competition, pricing pressure, and the need for companies to continuously innovate to stay ahead of the curve.